Dataset Information

Systematic Proteome-Wide Target Interrogation of PROTAC activity by High-Throughput DIA-MS on the Orbitrap Astral Platform

ABSTRACT: An efficient degradation-based proteomics workflow was established using data-independent acquisition-mass spectrometry (DIA-MS) and the Orbitrap Astral platform to investigate the mode of actions (MOA) and on target specificity of bromodomain and extra-terminal (BET) protein-targeting PROTACs, MZ1 and dBET6. Human cancerous and noncancerous cell lines (HeLa, MDA-MB-231 and HEK293) were treated with 1 µM of the PROTACs and their respective negative control controls (cis-MZ1 and dBET6Me) for 1 h and 24 h. Following treatment, cell pellets were harvested, proteins were processed and analysed in a 96-well plate format to identify proteins dysregulated at each timepoint. This approach successfully identified the three BET family members, bromodomain containing proteins 2/3/4 (BRD2, BRD3, BRD4) as the primary targets of MZ1 and dBET6 from the total proteomes of 9,641, 8,157 and 8,988 quantified proteins in HEK293, HeLa and MDA-MB-231 cells, respectively, after short (1 h) treatment. Extended treatment (24 h) with MZ1 and dBET6 further revealed 51, 57 and 115 secondary proteins significantly perturbed (|log2 fold change (log2FC)| ≥ 1 and adjusted p (adj.p) ≤ 0.05) in HEK293, HeLa and MDA-MB-231 cells, respectively. Overall, this work demonstrates the feasibility of the developed approach for identifying direct PROTAC targets following short incubations, as well as elucidating downstream proteomic alterations upon prolonged treatment, surpassing the resolution achievable by traditional immunoblotting techniques.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

SUBMITTER: Ghizal Siddiqui

LAB HEAD: Manuela Jorg

PROVIDER: PXD069438 | Pride | 2026-03-05

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20240119_124457_Chuhui-PROTAC-Exp1_Report.tsv	Tabular
	20240904_115057_Chuhui-Mz1vsciz-mz1_Report.tsv	Tabular
	20250129_121316_HEK293-dBET6-1h-24H-vs-dBET6Me_Report-v1.tsv	Tabular
	20250129_124419_HELA-dBET6-1h-24h-vsdBET6Me_Report.tsv	Tabular
	20250129_125008_HELA-MZ1-1h-24h-vs-cisMZ1_Report.tsv	Tabular

Items per page:

1 - 5 of 146

Similar Datasets

Project description:Malaria remains a global health threat, with rising drug resistance accelerating the urgent need for new therapeutics. Target elucidation is a critical step in antimalarial drug discovery, enabling a deeper understanding of the molecular mechanisms of action of both existing and novel compounds. This study validates solvent-induced proteome profiling (SPP) as a proteomics-based approach for identifying drug-protein interactions in Plasmodium falciparum. SPP de-tects shifts in protein stability induced by ligand binding, allowing the identification of drug target/s without the need for compound modifications. Here, we successfully generated solvent denaturation curves for the P. falciparum pro-teome, and demonstrated the utility of SPP with five antimalarial compounds: pyrimethamine, atovaquone, cipar-gamin, MMV1557817 and OSM-S-106. In addition to measuring each compound’s impact across the full denatura-tion curve, investigating protein levels at individual solvent percentages preserved specific stability changes that would otherwise be masked in pooled analyses performed by integral SPP. This strategy was critical for the identifi-cation of the cipargamin target, non-SERCA-type Ca2+-transporting P-ATPase (PfATP4). Notably, we propose live-cell treatment SPP as a novel approach, demonstrating its ability to identify the validated target of pyrimethamine, bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR), with high specificity. We also introduced the novel one-pot mixed-drug SPP, which enables the evaluation of multiple drugs within a single lysate and experi-mental setup. This alternative method simplifies the experimental workflow and includes positive controls to affirm the performance of the experiment. Overall, this study demonstrates that SPP can be successfully applied in both ly-sate and live-cell treatment conditions to elucidate drug targets in P. falciparum, as well as providing additional in-formation regarding the mechanisms of drug action, offering insights for the optimisation of existing antimalarials and the development of novel therapies.

Dataset Information

Systematic Proteome-Wide Target Interrogation of PROTAC activity by High-Throughput DIA-MS on the Orbitrap Astral Platform

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets